Results 31 to 40 of about 15,436 (169)

Transthyretin amyloid cardiomyopathy

Ugeskrift for Læger
Transthyretin amyloidosis (ATTR-CM) is an infiltrative cardiomyopathy caused by the deposition of amyloid fibrils, leading to heart failure, arrhythmias, and increased mortality. ATTR-CM prevalence is rising. The first disease-modifying drugs have been approved and implemented in Denmark.
Sie Kronborg, Fensman, Ale Hussein Jaber, Mejren, Tor Skibsted, Clemmensen, Steen Hvitfeldt, Poulsen   +3 more
  +8 more sources

Abdominal fat pad biopsies exhibit good diagnostic accuracy in patients with suspected transthyretin amyloidosis

Orphanet Journal of Rare Diseases, 2020
Background The diagnostic accuracy of histopathological detection of transthyretin amyloid (ATTR) by Congo red staining of abdominal fat samples has been questioned since low sensitivity has been reported, especially for patients with ATTR cardiomyopathy.
Hedvig Paulsson Rokke, Nima Sadat Gousheh, Per Westermark, Ole B. Suhr, Intissar Anan, Elisabet Ihse, Björn Pilebro, Jonas Wixner   +7 more
doaj   +1 more source

A Case of Early Hereditary Transthyretin Amyloid Cardiomyopathy Recognition With Genetic Screening: A Case Report

Journal of Primary Care & Community Health, 2022
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is one of the most common types of cardiac amyloidosis. Amyloid cardiomyopathy more commonly affects men, elderly, and 3% to 4% of the African-American population. ATTR-CM suspicion and diagnosis
Michel Juarez, Gaspar Del Rio-Pertuz, Kanak Parmar, Melanie C. Bois, Scott Shurmur, Erwin Argueta-Sosa   +5 more
doaj   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE‐CM, a Randomized Controlled Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Transthyretin amyloid cardiomyopathy (ATTR‐CM) carries high risk for all‐cause mortality (ACM), cardiovascular mortality (CVM), and cardiovascular hospitalization (CVH). NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) and serum TTR (sTTR)
Onyedika John Ilonze, Daniel Philip Judge, Ahmad Masri, Prem Soman, Francesco Cappelli, Michel Georges Khouri, Nitasha Sarswat, Mazen Hanna, Yuxi Liu, Gillian Murtagh, Kuangnan Xiong, Adam Castaño, Jean‐François Tamby, Jonathan C. Fox, Uma Sinha, Jan Marie Griffin, Julian D. Gillmore, James Louis Januzzi   +17 more
doaj   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
wiley   +1 more source

A phenomap of TTR amyloidosis to aid diagnostic screening

ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +4 more
wiley   +1 more source

NON-VAL30MET-TRANSTHYRETIN AMYLOID CARDIOMYOPATHY. LITERATURE REVIEW AND CLINICAL CASE

Российский кардиологический журнал, 2018
A literature review presented, with a clinical observation of non-Val30Mettransthyretin amyloid cardiomyopathy. Modern diagnostic and management algorithms discussed.
A. Ya. Gudkova, A. A. Poliakova, А. V. Amelin, O. М. Moiseeva, А. N. Krutikov, V. М. Tishkova, R. V. Grozov, D. V. Ryzhkova, T. V. Makurova, A. A. Kostareva, E. N. Semernin, E. V. Shlyakhto   +11 more
doaj   +1 more source